Last reviewed · How we verify
Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease
Approved treatments
- Velsipity · Pfizer Inc.
Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease patent landscape — cliff calendar, originator estates, attackable patents
- Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease treatment landscape brief
- Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease treatment updates RSS
Frequently asked questions about Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease
What drugs treat Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease?
Tracked treatments include Velsipity.
What is the treatment for Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease?
Standard treatment for Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease includes Velsipity. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease patent cliff · Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease CI report
- Treatment: Velsipity · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing